3 Asian Stocks Estimated To Be Up To 43.1% Below Intrinsic Value

In This Article:

As global markets navigate a landscape of economic uncertainty and shifting policies, Asian stocks present intriguing opportunities for investors seeking value. In this environment, identifying undervalued stocks—those trading below their intrinsic value—can be a prudent strategy to potentially capitalize on market inefficiencies.

Top 10 Undervalued Stocks Based On Cash Flows In Asia

Name

Current Price

Fair Value (Est)

Discount (Est)

Consun Pharmaceutical Group (SEHK:1681)

HK$8.87

HK$17.63

49.7%

RACCOON HOLDINGS (TSE:3031)

¥957.00

¥1890.86

49.4%

Sichuan Kexin Mechanical and Electrical EquipmentLtd (SZSE:300092)

CN¥13.10

CN¥25.69

49%

TechnoPro Holdings (TSE:6028)

¥3306.00

¥6593.98

49.9%

S Foods (TSE:2292)

¥2556.00

¥5084.09

49.7%

Bide Pharmatech (SHSE:688073)

CN¥54.00

CN¥106.91

49.5%

Takara Bio (TSE:4974)

¥866.00

¥1698.81

49%

ALUX (KOSDAQ:A475580)

₩11250.00

₩22243.70

49.4%

Kinsus Interconnect Technology (TWSE:3189)

NT$93.10

NT$182.94

49.1%

Zhejiang Juhua (SHSE:600160)

CN¥24.28

CN¥47.60

49%

Click here to see the full list of 272 stocks from our Undervalued Asian Stocks Based On Cash Flows screener.

Below we spotlight a couple of our favorites from our exclusive screener.

Smoore International Holdings

Overview: Smoore International Holdings Limited is an investment holding company that provides vaping technology solutions and has a market cap of HK$83.08 billion.

Operations: The company generates revenue primarily from the sale of APV and vaping devices and components, amounting to CN¥11.80 billion.

Estimated Discount To Fair Value: 13.7%

Smoore International Holdings is trading at HK$13.66, below its estimated fair value of HK$15.83, suggesting potential undervaluation based on cash flows. Earnings are forecast to grow significantly at 24.94% annually, outpacing the Hong Kong market's growth rate. However, recent financial results show a decline in net income from CNY 1,645.09 million to CNY 1,303.26 million year-over-year despite increased sales revenue to CNY 11.80 billion from CNY 11.20 billion.

SEHK:6969 Discounted Cash Flow as at Mar 2025
SEHK:6969 Discounted Cash Flow as at Mar 2025

Ningbo Sanxing Medical ElectricLtd

Overview: Ningbo Sanxing Medical Electric Co., Ltd. manufactures and sells power distribution and utilization systems both in China and internationally, with a market cap of CN¥41.34 billion.

Operations: The company generates revenue from the manufacture and sale of power distribution and utilization systems, serving both domestic and international markets.